Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClearPoint NeuroCLPT -1.54%63 Days Inventory is 190.22 as of Jun. 2026, which is 30% below its 10-year median of 272.63. GuruFocus rates CLPT with a GF Score™ of 63/100 and a GF Value™ of $14.14 (Fairly Valued). The stock has 8 warning signs investors should review. Among 788 Medical Devices & Instruments companies, ClearPoint Neuro ranks worse than 50.38% on this metric.
The historical rank and industry rank for ClearPoint Neuro's Days Inventory or its related term are showing as below:
CLPT'
s Days Inventory Range Over the Past 10 Years
Min: 178.34 Med: 272.63 Max: 370.23
Current: 178.34
During the past 13 years, ClearPoint Neuro's highest Days Inventory was 370.23. The lowest was 178.34. And the median was 272.63.
CLPT's Days Inventory is ranked worse than 50.38% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 177.16
vs CLPT: 178.34
ClearPoint Neuro's Days Inventory
increased
from Jun. 2025 (160.54) to Jun. 2026 (190.22).
It might indicate that ClearPoint Neuro's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
ClearPoint Neuro's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.48.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ClearPoint Neuro's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.80.
ClearPoint Neuro (NAS:CLPT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
ClearPoint Neuro's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ClearPoint Neuro's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
ClearPoint Neuro Days Inventory Related Terms
ClearPoint Neuro Days Inventory Historical Data
* Premium members only.
The historical data trend for ClearPoint Neuro's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ClearPoint Neuro's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClearPoint Neuro Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Days Inventory distribution charts can be found below:
* The bar in red indicates where ClearPoint Neuro's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro (CLPT) has a Days Inventory of 190.22 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ClearPoint Neuro and its competitors. This is 30% below median its historical median of 272.63. Over the past decade, ClearPoint Neuro's Days Inventory has ranged from 178.34 to 370.23. According to the industry distribution chart, ClearPoint Neuro ranks #397 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 50.4%.
Is ClearPoint Neuro's Days Inventory too high?
ClearPoint Neuro's current Days Inventory of 190.22 is 30% below median its 10-year median of 272.63. Over the past 10 years, this metric has ranged from a low of 178.34 to a high of 370.23. The Medical Devices & Instruments industry median Days Inventory is 177.16. ClearPoint Neuro's value of 190.22 is 7.4% above this industry median. Based on the distribution chart, ClearPoint Neuro ranks #397 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ClearPoint Neuro has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's Days Inventory compare to SI and PACB?
According to the Medical Devices & Instruments industry distribution chart, ClearPoint Neuro ranks #397 out of 788 companies for Days Inventory. This places ClearPoint Neuro in the lower half of its industry. The industry median Days Inventory is 177.16. ClearPoint Neuro's value of 190.22 is 7.4% above this benchmark. Historically, ClearPoint Neuro's own Days Inventory has ranged from 178.34 to 370.23 over the past decade. While the company's 10-year median is 272.63 vs. the industry median of 177.16, ClearPoint Neuro has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 177.16, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ClearPoint Neuro's current Days Inventory of 190.22 is 7.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on ClearPoint Neuro and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 177.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClearPoint Neuro's current Days Inventory is 190.22, which is 30% below median its own 10-year median of 272.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.14, compared to a current price of $14.66 — trading 3.7% above its estimated fair value. The current Days Inventory is 190.22, which is 30% below median its 10-year median of 272.63 and 7.4% above the Medical Devices & Instruments industry median of 177.16. ClearPoint Neuro's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current Days Inventory is 190.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClearPoint Neuro (CLPT) Overvalued in 2026?
Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be overvalued.
The current stock price of $14.66 is trading 3.7% above its estimated GF Value™ of $14.14.
GuruFocus considers ClearPoint Neuro to be Fairly Valued.
Key valuation signals for CLPT:
Days Inventory: 190.22 (30% below median its 10-year median of 272.63)
GF Value™: $14.14 vs. price of $14.66 (3.7% above fair value)
Industry Position: 7.4% above the Medical Devices & Instruments median (#397 of 788)
No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
63GF Score
Get the complete analysis for CLPT
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPT has been successfully added to your 
